Avoro Capital Advisors’s PMV Pharmaceuticals PMVP Stock Holding History

Avoro Capital Advisors’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-3,000,000	Closed	-$18.4M	–	47
2023 Q3	$18.4M	Sell	3,000,000 -60,000	-2%	-$413K	0.29%	33
2023 Q2	$19.2M	Hold	3,060,000	–	–	0.26%	34
2023 Q1	$14.6M	Hold	3,060,000	–	–	0.22%	33
2022 Q4	$26.6M	Hold	3,060,000	–	–	0.4%	30
2022 Q3	$36.4M	Sell	3,060,000 -40,000	-1%	-$578K	0.67%	24
2022 Q2	$44.2M	Buy	3,100,000 +900,000	+41%	+$13.1M	0.87%	21
2022 Q1	$45.8M	Buy	2,200,000 +735,000	+50%	+$13M	0.84%	21
2021 Q4	$33.8M	Sell	1,465,000 -1,460,000	-50%	-$35.3M	0.58%	29
2021 Q3	$87.2M	Buy	2,925,000 +1,100,000	+60%	+$35.1M	1.37%	18
2021 Q2	$62.3M	Sell	1,825,000 -535,267	-23%	-$17.9M	1.08%	20
2021 Q1	$77.6M	Buy	2,360,267 +10,000	+0.4%	+$394K	1.34%	17
2020 Q4	$131M	Buy	2,350,267 +500,267	+27%	+$19.6M	2.25%	15
2020 Q3	$57.6M	Buy	+1,850,000	New	+$68.1M	0.82%	24

Other funds holding PMVP

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Avoro Capital Advisors's PMVP Position: Q4 2023 in Review

Avoro Capital Advisors sold out of PMV Pharmaceuticals (PMVP) in Q4 2023, closing a stake of 3,000,000 shares — an estimated $18.4M sold.

Avoro Capital Advisors first reported a position in PMVP in Q3 2020 and held it in 13 quarters. The position peaked at $131M in Q4 2020. 98 funds tracked by Wall St. Rank hold PMVP as of Q4 2023.

Avoro Capital Advisors reported no remaining PMV Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Avoro Capital Advisors sold 3,000,000 PMV Pharmaceuticals shares in Q4 2023, an estimated $18.4M.
Avoro Capital Advisors first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 13 quarters.
Avoro Capital Advisors's PMV Pharmaceuticals position peaked at $131M in Q4 2020.
98 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q4 2023.

Based on Avoro Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.